Aberrant splicing of cyclin-dependent kinase-associated protein phosphatase KAP increases proliferation and migration in glioblastoma.

The cyclin-dependent kinase (Cdk)-associated protein phosphatase KAP is a dual-specificity phosphatase of which the only known function is to dephosphorylate Cdk2 and inhibit cell cycle progression. Paradoxically, we find increased KAP mRNA expression in malignant astrocytomas, which correlates with increasing histologic grade and decreased patient survival. We have resolved this apparent paradox with the discovery of aberrant KAP splicing in malignant astrocytomas that leads to increased expression of KAP-related transcripts but decreased KAP protein expression. In addition, the aberrant splicing generates a dominant negative KAP variant that increases proliferation. We provide the first evidence that KAP not only regulates proliferation but also inhibits migration by decreasing cdc2 mRNA and protein expression. The effect of KAP on cdc2 expression requires its phosphatase activity but does not involve direct dephosphorylation of cdc2. Thus, KAP regulates both cdc2-dependent migration and Cdk2-dependent proliferation, and its loss due to aberrant splicing increases malignancy in human gliomas.

[1]  Taro Shirakawa,et al.  Binding of HTm4 to Cyclin-dependent Kinase (Cdk)-associated Phosphatase (KAP)·Cdk2·Cyclin A Complex Enhances the Phosphatase Activity of KAP, Dissociates Cyclin A, and Facilitates KAP Dephosphorylation of Cdk2* , 2005, Journal of Biological Chemistry.

[2]  J. Venables.  Aberrant and Alternative Splicing in Cancer , 2004, Cancer Research.

[3]  P. Kaldis,et al.  Cell Cycle Sibling Rivalry: Cdc2 Versus Cdk2 , 2005 .

[4]  A. Woodard,et al.  αvβ3 integrin expression up-regulates cdc2, which modulates cell migration , 2003, The Journal of cell biology.

[5]  Wei Zhang,et al.  Inactivation of the invasion inhibitory gene IIp45 by alternative splicing in gliomas. , 2005, Cancer research.

[6]  Roger Brent,et al.  C dil, a Human Gl and S Phase Protein Phosphatase That Associates with Cdk2 , 2003 .

[7]  A. Chenn,et al.  A cell behavior screen: identification, sorting, and enrichment of cells based on motility , 2005, BMC Cell Biology.

[8]  T. Hunter,et al.  Dephosphorylation of Cdk2 Thr160 by the Cyclin-Dependent Kinase-Interacting Phosphatase KAP in the Absence of Cyclin , 1995, Science.

[9]  K. Silina,et al.  Alterations of pre‐mRNA splicing in cancer , 2005, Genes, chromosomes & cancer.

[10]  Chin-Lee Wu,et al.  Aberrant splicing of cables gene, a CDK regulator, in human cancers , 2005, Cancer biology & therapy.

[11]  N P Burrows,et al.  A point mutation in an intronic branch site results in aberrant splicing of COL5A1 and in Ehlers-Danlos syndrome type II in two British families. , 1998, American journal of human genetics.

[12]  S. Horvath,et al.  Gene Expression Profiling of Gliomas Strongly Predicts Survival , 2004, Cancer Research.

[13]  B. Graveley.  Alternative splicing: increasing diversity in the proteomic world. , 2001, Trends in genetics : TIG.

[14]  Kai-jin Xu,et al.  Intestinal microflora in rats with ischemia/reperfusion liver injury. , 2005, Journal of Zhejiang University. Science. B.

[15]  P. Cohen,et al.  The specificities of protein kinase inhibitors: an update. , 2003, The Biochemical journal.

[16]  Stuart A. Aaronson,et al.  Overexpression of Kinase-Associated Phosphatase (KAP) in Breast and Prostate Cancer and Inhibition of the Transformed Phenotype by Antisense KAP Expression , 2000, Molecular and Cellular Biology.

[17]  J. G. Patton,et al.  GH1 splicing is regulated by multiple enhancers whose mutation produces a dominant-negative GH isoform that can be degraded by allele-specific small interfering RNA (siRNA). , 2004, Endocrinology.

[18]  Y. Liaw,et al.  Aberrant transcripts of the cyclin-dependent kinase-associated protein phosphatase in hepatocellular carcinoma. , 2000, Cancer research.

[19]  C. Yeh,et al.  Abolishment of the interaction between cyclin-dependent kinase 2 and Cdk-associated protein phosphatase by a truncated KAP mutant. , 2003, Biochemical and biophysical research communications.

[20]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[21]  G. Hannon,et al.  KAP: a dual specificity phosphatase that interacts with cyclin-dependent kinases. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[22]  D O Morgan,et al.  Cyclin-dependent kinases: engines, clocks, and microprocessors. , 1997, Annual review of cell and developmental biology.

[23]  David E. Misek,et al.  Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. , 2001, Cancer research.

[24]  J. Kutok,et al.  Human HTm4 is a hematopoietic cell cycle regulator. , 2002, The Journal of clinical investigation.

[25]  L. Johnson,et al.  Phosphoprotein-protein interactions revealed by the crystal structure of kinase-associated phosphatase in complex with phosphoCDK2. , 2001, Molecular cell.

[26]  M. Tanudji,et al.  Unmasking the Redundancy Between Cdk1 and Cdk2 at G2 Phase in Human Cancer Cell Lines , 2006, Cell cycle.

[27]  G. Fuller,et al.  Fibroblast growth factor receptor-1 alpha-exon exclusion and polypyrimidine tract-binding protein in glioblastoma multiforme tumors. , 2000, Cancer research.

[28]  G L Snyder,et al.  Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. , 2000, European journal of biochemistry.

[29]  M. Møller,et al.  Molecular control of the cell cycle in cancer: biological and clinical aspects. , 2003, Danish medical bulletin.